News

Switching to Ocrevus (ocrelizumab) within a relatively short period is a safe and effective option for people with relapsing-remitting multiple sclerosis (RRMS) who stop treatment with Tysabri (natalizumab), a small and retrospective analysis suggests. With a median washout period of six weeks between therapies, the 28 patients in this study…

Mavenclad (cladribine) prevents relapses and disease progression in more than half of patients with relapsing forms of multiple sclerosis (MS) for at least five years after the last dose, according to a real-life study from Italy. These findings, based on real-world data from Italian MS patients previously treated…

The German Federal Ministry of Education and Research (BMBF) has granted €1.2 million ($1.35 million) to support a project seeking to characterize the function of the protein TRPM4, a potential therapeutic target to prevent nerve cell injury associated with multiple sclerosis (MS), and to develop new drug candidates…

Young men, ages 16 to 20, with a higher the body mass index (BMI) are at greater their risk of being diagnosed with multiple sclerosis (MS) later in life, regardless of physical fitness, according to a Swedish study. Risk rose across “the entire BMI range,” its researchers reported,…

Tecfidera (dimethyl fumarate) is as safe and effective in Hispanic/Latino multiple sclerosis (MS) patients as it is in their non-Hispanic and non-Latino peers, three-year data from a real-world study show. These interim findings, based on the largest group of Tecfidera-treated Hispanic and Latino MS patients studied to date, support the therapy’s…

The University of Alberta and PROTXX are collaborating to develop wearable sensors for people with multiple sclerosis (MS) and advance a remote healthcare platform that facilitates personalized care and reduces frequency of hospital visits. The wearable sensors will help monitor neurological, sensory, and musculoskeletal symptoms without the need to…

Osmotica Pharmaceuticals has submitted an amended new drug application (NDA) to the U.S. Food and Drug Administration (FDA) requesting the approval of arbaclofen extended release (ER) tablets for the treatment of spasticity in people with multiple sclerosis (MS). Arbaclofen ER (brand name…

Comorbidities such as anxiety and depression are associated with a significantly increased risk of relapse in people with relapsing-remitting multiple sclerosis (RRMS), a clinical trial analysis has found.  Anxiety and abnormal blood lipids (fats) also increased the risk of any RRMS disease activity.  Based on those findings, researchers…

Exposure to disease-modifying therapies does not increase multiple sclerosis (MS) patients’ risk of developing a severe form of COVID-19, according to a registry-based study. However, MS patients who are older, obese, or have severe neurological impairments have a greater risk of developing a severe form of the disease. Findings…

GeNeuro announced that a first multiple sclerosis (MS) patient has enrolled in its Phase 2 trial assessing the safety and effectiveness of temelimab in people whose disease is progressing in the absence of relapses. This trial, taking place at the Karolinska Institutet’s Academic Specialist Center (ASC), in Stockholm, had been postponed to reduce…

Loss of myelin in nerve cell fibers — the hallmark of multiple sclerosis (MS) — leads to a shortage of mitochondria, a cell’s powerhouse, denying these damaged fibers the energy they need to work as intended, a new study shows. Boosting the migration of mitochondria to affected nerve…

Tecfidera (dimethyl fumarate) is safe and effective as a long-term treatment for relapsing-remitting multiple sclerosis (RRMS), a study of clinical trial data covering up to 11 years of treatment suggests. The study, “Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis:…

Novartis has awarded a total of $300,000 to two tech companies, honoring each for work done to improve the mobility and independence of people living with multiple sclerosis (MS). The top winner of the Novartis Innovation Prize: Assistive Tech for…

MyHealthTeams and EMD Serono have teamed up to launch the Treatment and Adherence Resource Center, a new informational tool within the MyMSTeam social network for people living with multiple sclerosis (MS). The new resource center is geared toward educating MS patients about the importance of starting…

The National Institute for Health and Care Excellence (NICE) is recommending against Mayzent (siponimod) as a treatment for active secondary progressive multiple sclerosis (SPMS) in the U.K., because its cost-effectiveness relative to an existing treatment for these patients is not known. NICE’s draft guidance for Mayzent is open…

People with multiple sclerosis (MS) exert increased caution with their walking pattern and take smaller steps overall, a study shows. These findings could contribute to the development of better walking rehabilitation programs and decrease the risk of falls. The study, “Influence of Multiple Sclerosis on Dynamic…

A first person has enrolled in Sanofi’s Phase 3 trial evaluating SAR442168, an oral BTK inhibitor intended to treat relapsing forms of multiple sclerosis (MS), Sanofi’s partner, Principia Biopharma, announced. “We are delighted that Sanofi has initiated … [this] trial in patients with relapsing MS,” Roy Hardiman, chief…

Psychosis and cognitive difficulties may be initial symptoms of relapsing‐remitting multiple sclerosis (RRMS), a case report says. “A case report revealing acute onset psychosis and cognitive impairment as primary manifestation in relapsing‐remitting multiple sclerosis” was published in the journal…

A study aiming to better understand falls and fall-related injuries in people with multiple sclerosis (MS) and other neurological disorders while self-isolating during the COVID-19 pandemic is recruiting participants. The online study, largely in the form of a questionnaire, is being carried out by the Motor Control Research…

Generic formulations of dimethyl fumarate — currently sold as Tecfidera by Biogen — were given a green light to enter the U.S. market, after a federal court invalidated a patent protecting Tecfidera from generic competition as a multiple sclerosis (MS) treatment.  The ruling by the District Court for the…

Adamas Pharmaceuticals has decided to stop further clinical development of ADS-5102 (amantadine), intended to help people with multiple sclerosis (MS) who have difficulties with walking. The decision came after the company reviewed findings from a comprehensive analysis of…

Cognitive problems are common in people with multiple sclerosis (MS) but inadequately addressed by disease-modifying therapies, while cognitive rehabilitation and exercise training programs can be effective, a review study reported.  Research studies of exercise programs need to include larger groups of patients with demonstrated cognitive difficulties, however, and more pharmacological…

A person infected through the skin by the hookworm Necator americanus shows a spike in  regulatory T-cells, specialized immune T-cells that work to limit inflammation, and a controlled infection by these generally safe worms may benefit some relapsing multiple sclerosis (MS) patients, research suggests. “The…

Gilenya (fingolimod), which works to modulate immune system activity in multiple sclerosis (MS), may benefit people with severe respiratory disease associated with COVID-19, a case report highlights. The study, “Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod,” was published in…

Atara Biotherapeutics has enrolled a first patient in a clinical trial testing ATA188, its off-the-shelf T-cell immunotherapy for people with progressive forms of multiple sclerosis (MS). The Phase 1b trial (NCT03283826) follows promising safety and tolerability results from its open-label Phase 1a part, including a…

Nearly 3,000 multiple sclerosis (MS) healthcare providers and researchers  convened recently to share their findings regarding the latest developments in the diagnosis and treatment of MS. However, unlike past meetings, this year’s 34th Annual Meeting of the Consortium of MS Centers (CMSC) took place online. Virtual presentations covered the…

Australian scientists have discovered subsets of immune cells that differ between people who have multiple sclerosis (MS) and those who don’t. Because the prevalence of these cells correlates with autoimmune attacks, they represent potential targets for MS therapies. The study, “IgG3 + B…

A likelihood of depression is two to three times higher in multiple sclerosis (MS) patients in the U.S. and U.K. than in similar groups of people in these countries without the disease, a study reported. This risk was also “most evident in the first five years after MS diagnosis” among…

Multiple sclerosis (MS) patients who are obese experience faster degeneration in optic nerve tissue than do those of normal weight, an observational study found. Since optic nerve degeneration correlates with greater nerve loss in the brain, measuring changes in this tissue may be a feasible way to determine…

Mapi Pharma, supported by an additional $20 million investment from its partner Mylan, will continue a Phase 3 trial assessing the safety, tolerability, and efficacy of GA Depot, its long-acting, once-a-month injectable formulation of glatiramer acetate. The study (NCT04121221), which opened in October 2019,…